Lobular Breast Cancer Alliance Closes the Market - TradingView
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - Christine Brezden-Masley, Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital and Medical Director of Cancer Program for Sinai Health System in Toronto, Dr. Sean Egan, Senior Scientist in the Cell and Systems Biology program at The Hospital for Sick Children ("SickKids") and a professor in the Department of Molecular Genetics at the University of Toronto, Antonio Cassano, Research Coordinator, Department of Surgery, Women's College Hospital, and Kimberly Carson, Chief Executive Officer, Breast Cancer Canada, joined Brenda Cunnington, Managing Director, Americas, Trayport at TMX Group, and Board Director for The Lobular Breast Cancer Alliance ("LBCA") to close the market in recognition of Lobular Breast Cancer Awareness Day. October is Breast Cancer Awareness month, and the 15th was selected as Lobular Breast Cancer Awareness Day to shine a spotlight on the 15% of breast cancer diagnoses each year that are invasive lobular carcinoma (ILC), also known as lobular breast cancer. As the second most common type of breast cancer, ILC receives less than 1% of breast cancer research funding
This article is an excerpt. To read the full content, visit the original source. TradingView
Related articles
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!